Current Treatment Options for REM Sleep Behaviour Disorder

The symptomatic treatment of REM sleep behaviour disorder (RBD) is very important to prevent sleep-related falls and/or injuries. Though clonazepam and melatonin are usually considered the first-line symptomatic therapy for RBD, their efficiency has not been proven by randomized clinical trials. The...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Félix Javier Jiménez-Jiménez, Hortensia Alonso-Navarro, Elena García-Martín, José A. G. Agúndez
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	REM sleep behaviour disorder neurochemistry neurotransmitters dopaminergic dysfunction noradrenalin acetylcholine Medicine R
Acceso en línea:	https://doaj.org/article/214b3a0b095e4c47bce25ae88714e879
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:214b3a0b095e4c47bce25ae88714e879
record_format	dspace
spelling	oai:doaj.org-article:214b3a0b095e4c47bce25ae88714e8792021-11-25T18:07:59ZCurrent Treatment Options for REM Sleep Behaviour Disorder10.3390/jpm111112042075-4426https://doaj.org/article/214b3a0b095e4c47bce25ae88714e8792021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1204https://doaj.org/toc/2075-4426The symptomatic treatment of REM sleep behaviour disorder (RBD) is very important to prevent sleep-related falls and/or injuries. Though clonazepam and melatonin are usually considered the first-line symptomatic therapy for RBD, their efficiency has not been proven by randomized clinical trials. The role of dopamine agonists in improving RBD symptoms is controversial, and rivastigmine, memantine, 5-hydroxytryptophan, and the herbal medicine yokukansan have shown some degree of efficacy in short- and medium-term randomized clinical trials involving a low number of patients. The development of potential preventive therapies against the phenoconversion of isolated RBD to synucleinopathies should be another important aim of RBD therapy. The design of long-term, multicentre, randomized, placebo-controlled clinical trials involving a large number of patients diagnosed with isolated RBD with polysomnographic confirmation, directed towards both symptomatic and preventive therapy for RBD, is warranted.Félix Javier Jiménez-JiménezHortensia Alonso-NavarroElena García-MartínJosé A. G. AgúndezMDPI AGarticleREM sleep behaviour disorderneurochemistryneurotransmittersdopaminergic dysfunctionnoradrenalinacetylcholineMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1204, p 1204 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	REM sleep behaviour disorder neurochemistry neurotransmitters dopaminergic dysfunction noradrenalin acetylcholine Medicine R
spellingShingle	REM sleep behaviour disorder neurochemistry neurotransmitters dopaminergic dysfunction noradrenalin acetylcholine Medicine R Félix Javier Jiménez-Jiménez Hortensia Alonso-Navarro Elena García-Martín José A. G. Agúndez Current Treatment Options for REM Sleep Behaviour Disorder
description	The symptomatic treatment of REM sleep behaviour disorder (RBD) is very important to prevent sleep-related falls and/or injuries. Though clonazepam and melatonin are usually considered the first-line symptomatic therapy for RBD, their efficiency has not been proven by randomized clinical trials. The role of dopamine agonists in improving RBD symptoms is controversial, and rivastigmine, memantine, 5-hydroxytryptophan, and the herbal medicine yokukansan have shown some degree of efficacy in short- and medium-term randomized clinical trials involving a low number of patients. The development of potential preventive therapies against the phenoconversion of isolated RBD to synucleinopathies should be another important aim of RBD therapy. The design of long-term, multicentre, randomized, placebo-controlled clinical trials involving a large number of patients diagnosed with isolated RBD with polysomnographic confirmation, directed towards both symptomatic and preventive therapy for RBD, is warranted.
format	article
author	Félix Javier Jiménez-Jiménez Hortensia Alonso-Navarro Elena García-Martín José A. G. Agúndez
author_facet	Félix Javier Jiménez-Jiménez Hortensia Alonso-Navarro Elena García-Martín José A. G. Agúndez
author_sort	Félix Javier Jiménez-Jiménez
title	Current Treatment Options for REM Sleep Behaviour Disorder
title_short	Current Treatment Options for REM Sleep Behaviour Disorder
title_full	Current Treatment Options for REM Sleep Behaviour Disorder
title_fullStr	Current Treatment Options for REM Sleep Behaviour Disorder
title_full_unstemmed	Current Treatment Options for REM Sleep Behaviour Disorder
title_sort	current treatment options for rem sleep behaviour disorder
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/214b3a0b095e4c47bce25ae88714e879
work_keys_str_mv	AT felixjavierjimenezjimenez currenttreatmentoptionsforremsleepbehaviourdisorder AT hortensiaalonsonavarro currenttreatmentoptionsforremsleepbehaviourdisorder AT elenagarciamartin currenttreatmentoptionsforremsleepbehaviourdisorder AT joseagagundez currenttreatmentoptionsforremsleepbehaviourdisorder
_version_	1718411547635613696

Current Treatment Options for REM Sleep Behaviour Disorder

Ejemplares similares